195 related articles for article (PubMed ID: 18284435)
1. Adiponectin and its response to thiazolidinediones are associated with insulin-mediated glucose metabolism in type 2 diabetic patients and their first-degree relatives.
Hulstrøm V; Højlund K; Vinten J; Beck-Nielsen H; Levin K
Diabetes Obes Metab; 2008 Nov; 10(11):1019-28. PubMed ID: 18284435
[TBL] [Abstract][Full Text] [Related]
2. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
3. The effect of pioglitazone on the liver: role of adiponectin.
Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA
Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
[TBL] [Abstract][Full Text] [Related]
4. Insulin signalling in skeletal muscle of subjects with or without Type II-diabetes and first degree relatives of patients with the disease.
Meyer MM; Levin K; Grimmsmann T; Beck-Nielsen H; Klein HH
Diabetologia; 2002 Jun; 45(6):813-22. PubMed ID: 12107725
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.
van Tits LJ; Arioglu-Oral E; Sweep CG; Smits P; Stalenhoef AF; Tack CJ
Neth J Med; 2005; 63(7):250-5. PubMed ID: 16093575
[TBL] [Abstract][Full Text] [Related]
7. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.
Højlund K; Glintborg D; Andersen NR; Birk JB; Treebak JT; Frøsig C; Beck-Nielsen H; Wojtaszewski JF
Diabetes; 2008 Feb; 57(2):357-66. PubMed ID: 17977950
[TBL] [Abstract][Full Text] [Related]
8. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.
Mathieu-Costello O; Kong A; Ciaraldi TP; Cui L; Ju Y; Chu N; Kim D; Mudaliar S; Henry RR
Metabolism; 2003 May; 52(5):540-6. PubMed ID: 12759881
[TBL] [Abstract][Full Text] [Related]
9. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.
Boden G; Homko C; Mozzoli M; Zhang M; Kresge K; Cheung P
Diabetes; 2007 Jan; 56(1):248-55. PubMed ID: 17192489
[TBL] [Abstract][Full Text] [Related]
10. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome.
Glintborg D; Frystyk J; Højlund K; Andersen KK; Henriksen JE; Hermann AP; Hagen C; Flyvbjerg A; Andersen M
Clin Endocrinol (Oxf); 2008 Feb; 68(2):165-74. PubMed ID: 17803698
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
12. Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease.
Qurashi S; Mynarcik DC; McNurlan MA; Ahn H; Ferris R; Gelato MC
Clin Sci (Lond); 2008 Sep; 115(6):197-202. PubMed ID: 18254722
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
14. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Varo N; Vicent D; Libby P; Nuzzo R; Calle-Pascual AL; Bernal MR; Fernández-Cruz A; Veves A; Jarolim P; Varo JJ; Goldfine A; Horton E; Schönbeck U
Circulation; 2003 Jun; 107(21):2664-9. PubMed ID: 12742991
[TBL] [Abstract][Full Text] [Related]
15. The role of troglitazone in treating the insulin resistance syndrome.
Granberry MC; Schneider EF; Fonseca VA
Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
[TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia.
Annuzzi G; Bozzetto L; Patti L; Santangelo C; Giacco R; Di Marino L; De Natale C; Masella R; Riccardi G; Rivellese AA
Metabolism; 2010 Apr; 59(4):567-74. PubMed ID: 19922965
[TBL] [Abstract][Full Text] [Related]
17. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
[TBL] [Abstract][Full Text] [Related]
18. Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes.
Levin K; Hother-Nielsen O; Henriksen JE; Beck-Nielsen H
Diabetes Care; 2004 Jan; 27(1):148-54. PubMed ID: 14693981
[TBL] [Abstract][Full Text] [Related]
19. Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients.
Hiramatsu S; Tajiri Y; Karashima T
Diabetes Obes Metab; 2004 May; 6(3):231-3. PubMed ID: 15056132
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
